Invizius
Entity

  • Invizius

    Created in 2018


  • Up & running (A)
    Existing signals show a regular activity

  • Social networks

    1,198

  • Activities

    deeptech healthtech

  • Technologies

    Synthetic Biology

  • Entity types

    SMB

  • Location

    Bo'Ness Rd, Newhouse, Chapelhall, Motherwell ML1 5UH, UK

    Newhouse

    United Kingdom

  • Employees

    Scale: 2-10

    Estimated: 9

  • Engaged catalyst

    0
    0 0

  • Added in Motherbase

    1 year, 11 months ago
Description
  • Value proposition

    Fighting Inflammation at its Source

    Invizius is a spin-out based on world-class Complement research carried out at the University of Edinburgh, Scotland.

    Complement is 1.3b years old and part of the innate immune system. As it is the most ancient part of the immune system it is involved at the beginning of every inflammatory response. We fight inflammation at its source.

    Invizius is developing Second Generation Complement Therapeutics to significantly improve the clinical outcomes of patients with dysregulated complement systems leading to inflammation and fibrosis.

    Our first indication for H-Guard is in Acute Kidney Injury receiving CRRT where there is filter membrane associated Complement driven damage to renal tubule cells as well as local and systemic inflammatory damage.

    Our second product Meso-Guard is for patients on Renal replacement Therapy receiving Peritoneal Dialysis. This product should extend the PD treatment window by reducing fibrotic changes caused by peritoneal dialysis fluid.

    Despite significant improvements in haemodialysis membranes Complement activation by contact with a foreign surface remains a serious issue with short, medium and long term clinical implications. Other acute application of H-Guard is for coating Cardiopulmonary Bypass and ECMO filters.

    Other applications of our platform include IgA Nephropathy, Preeclampsia, SLE and Neuroinflammation.



    Nephrology, Fibrosis, Neurology, Autoimmunity, Diabetes, Complement, Immunology, and Inflammation

  • Home - Invizius - second generation complement therapeutics for autoimmune and inflammatory disorders

    Invizius is developing products to help patients on dialysis, cardiopulmonary bypass, ECMO and on other extra-corporeal treatments, to feel better, and suffer fewer complications.

    • https://www.invizius.com/
Catalyst interactions
Catalyst Type Tweets Articles
No interactions
Social network dynamics
Similar entities
BETA
Last news
Show all articles